Amyloid Plaques

The International Working Group has updated diagnostic guidelines for Alzheimer’s disease to include individuals with normal cognition who test positive for core biomarkers indicative of disease pathology.

AC Immune SA ad Takeda have announced an exclusive, worldwide option and license agreement for the former’s active immunotherapies that target toxic forms of the biomarker amyloid beta to treat Alzheimer’s disease.

PHILADELPHIA — Safe and effective ways to introduce anti-amyloid medications for Alzheimer’s disease depends on comprehensive care infrastructure from screening to administration, according to a speaker.

Quest Diagnostics has announced the availability of a blood-based test that assesses the risk of developing Alzheimer’s disease through amyloid-beta biomarkers.

Donanemab “significantly” slowed clinical progression of Alzheimer’s disease in those with low to medium or high tau pathology, according to a poster presentation at the Alzheimer’s Association International Conference.

The FDA has granted Eisai full approval for Leqembi to treat adults with Alzheimer’s disease.

BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque reductions at 6 months with donanemab vs. aducanumab, according to a presentation at the American Academy of Neurology annual meeting.

Individuals who consumed MIND and Mediterranean diets had fewer amyloid plaques and tau tangles in their brain, which are indicators of Alzheimer’s disease, according to researchers.

The FDA granted breakthrough device designation and permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

The American Academy of Neurology has issued ethical guidance on Aduhelm that outlines important points for neurologists to communicate to patients eligible for the treatment.